This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Why Sight Sciences (SGHT) Might Surprise This Earnings Season
by Zacks Equity Research
Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 121.5% upside potential for Sight Sciences, Inc. (SGHT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Quotient (QTNT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quotient (QTNT) delivered earnings and revenue surprises of -32.14% and 6.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Globus Medical (GMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 3.70% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Doximity's (DOCS) fiscal first-quarter results are likely to reflect continued strength in its fax, e-signature and telehealth products.
Bears are Losing Control Over Sight Sciences, Inc. (SGHT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 200% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 199.7% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
3 Medical Device Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
The Medical device companies' Q4 results are likely to reflect base business recovery on a year-over-year basis. Let's see how PRGO, COO and SGHT are poised ahead of their earnings releases.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
Why Earnings Season Could Be Great for Sight Sciences (SGHT)
by Zacks Equity Research
Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Predict a 73% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 68% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 67.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.